Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Queensland Health
Julphar
Argus Health
Merck
Fish and Richardson
Express Scripts
Covington
QuintilesIMS

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MESTINON

« Back to Dashboard

Clinical Trials for Mestinon

Trial ID Title Status Sponsor Phase Summary
NCT00075101 Sleep, Fatigue, and Dexamethosone in Children With Leukemia Completed National Institute of Nursing Research (NINR) Phase 3 The purpose of this study is to determine the relationship between dexamethosone (steroid) and children's sleep and fatigue.
NCT00276406 Use of Pyridostigmine for Constipation in Diabetics Completed National Center for Research Resources (NCRR) Phase 1/Phase 2 Doctors at Mayo Clinic are doing this study to learn if pyridostigmine, a drug, affects the speed at which food travels through the stomach, intestines and colon, and if pyridostigmine improves constipation symptoms in patients with diabetes. Pyridostigmine has been approved by the Food and Drug Administration (FDA) for routine clinical use, however, its use as proposed in this study is considered investigational.
NCT00276406 Use of Pyridostigmine for Constipation in Diabetics Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 1/Phase 2 Doctors at Mayo Clinic are doing this study to learn if pyridostigmine, a drug, affects the speed at which food travels through the stomach, intestines and colon, and if pyridostigmine improves constipation symptoms in patients with diabetes. Pyridostigmine has been approved by the Food and Drug Administration (FDA) for routine clinical use, however, its use as proposed in this study is considered investigational.
NCT00276406 Use of Pyridostigmine for Constipation in Diabetics Completed Mayo Clinic Phase 1/Phase 2 Doctors at Mayo Clinic are doing this study to learn if pyridostigmine, a drug, affects the speed at which food travels through the stomach, intestines and colon, and if pyridostigmine improves constipation symptoms in patients with diabetes. Pyridostigmine has been approved by the Food and Drug Administration (FDA) for routine clinical use, however, its use as proposed in this study is considered investigational.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Mestinon

Condition Name

Condition Name for Mestinon
Intervention Trials
Diabetes Mellitus 3
Immuno-senescence 1
CD4+ T Lymphocytopenia 1
Postural Tachycardia Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Mestinon
Intervention Trials
HIV Infections 3
Diabetes Mellitus 3
Tachycardia 2
Acquired Immunodeficiency Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Mestinon

Trials by Country

Trials by Country for Mestinon
Location Trials
United States 7
Denmark 2
Mexico 2
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Mestinon
Location Trials
New York 2
Tennessee 2
Florida 1
Oregon 1
Minnesota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Mestinon

Clinical Trial Phase

Clinical Trial Phase for Mestinon
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Mestinon
Clinical Trial Phase Trials
Recruiting 6
Completed 4
Active, not recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Mestinon

Sponsor Name

Sponsor Name for Mestinon
Sponsor Trials
National Institutes of Health (NIH) 2
University of Aarhus 2
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Mestinon
Sponsor Trials
Other 17
NIH 7
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Johnson and Johnson
Accenture
Cipla
Fish and Richardson
Farmers Insurance
US Army
Chubb
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.